The FDA has narrowly beaten the European Medicines Agency (EMA) to the most approved drugs with a new active substance in ...
The FDA has approved Cobenfy, a new drug to treat people with schizophrenia that comes with fewer side effects.
Analyst David Risinger of Leerink Partners reiterated a Buy rating on Bristol-Myers Squibb (BMY – Research Report), retaining the price target ...
Among the 55 novel drugs that crossed the regulatory finish line last year were notable new mechanisms of action, coming ...
The FDA wrapped up 2024 with 50 new drug approvals, clearing a wave of long-awaited treatments. Meanwhile, Transcarent will ...
Bristol Myers Squibb CEO Chris Boerner described his company's new drug, Cobenfy, which can be used to treat psychiatric disorders like schizophrenia. He said the treatment is effective but doesn ...
AbbVie's $3.5 Billion Blow: Can Bold Bets Revive Its Profit Forecasts?
Coventry City are unbeaten across their past four home league games against Bristol City (W2 D2), since a 3-1 loss in October ...